Relationship between Serum Bortezomib Concentration and Emergence of Diarrhea in Patients with Multiple Myeloma and/or AL Amyloidosis

(1) Background: multiple myeloma patients have benefited from bortezomib therapy, though it has often been discontinued owing to diarrhea. The objective of this study was to verify serum bortezomib concentration in the emergence of diarrhea. (2) Methods: this prospective, observational case-control,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yuki Fujimoto, Shikiko Ueno, Kazutaka Oda, Nao Gunda, Yumi Shimomura, Yuka Nishimura, Ayami Yamaguchi, Akari Kuwano, Yuki Ito, Yusuke Baba, Aina Nishigaki, Natsumi Michiwaki, Shota Uchino, Kayo Kurogi, Yawara Kawano, Masao Matsuoka, Hideyuki Saito, Yutaka Okuno, Hirofumi Jono
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	multiple myeloma bortezomib diarrhea serum concentration discontinuation Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/e6d83d1c31f744fe8db46174da7bb086
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e6d83d1c31f744fe8db46174da7bb086
record_format	dspace
spelling	oai:doaj.org-article:e6d83d1c31f744fe8db46174da7bb0862021-11-25T17:02:32ZRelationship between Serum Bortezomib Concentration and Emergence of Diarrhea in Patients with Multiple Myeloma and/or AL Amyloidosis10.3390/cancers132256742072-6694https://doaj.org/article/e6d83d1c31f744fe8db46174da7bb0862021-11-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/22/5674https://doaj.org/toc/2072-6694(1) Background: multiple myeloma patients have benefited from bortezomib therapy, though it has often been discontinued owing to diarrhea. The objective of this study was to verify serum bortezomib concentration in the emergence of diarrhea. (2) Methods: this prospective, observational case-control, and monocentric study was performed with an approval by the Ethics Committee of Kumamoto University Hospital in 2015 (No. 1121) from February 2015 to April 2017. (3) Results: twenty-four patients with bortezomib therapy were recruited; eight patients (33.3%) developed diarrhea at day 3 as median. Median measured trough bortezomib concentration at 24 h after first or second dose for patients with or without diarrhea was 0.87 or 0.48 ng/mL, respectively (<i>p =</i> 0.04, Wilcoxon signed rank test). Receiver operation characteristic (ROC) analysis produced the cut-off concentration of 0.857 ng/mL (area under the ROC curve of 0.797, sensitivity of 0.625, specificity of 0.875). The survival curves between patients with and without diarrhea were similar (<i>p =</i> 0.667); those between patients with higher and lower concentration than median value (0.61 ng/mL) were also similar (<i>p =</i> 0.940). (4) Conclusions: this study indicated the possible involvement of serum bortezomib concentration in the emergence of diarrhea in bortezomib therapy in patients with multiple myeloma.Yuki FujimotoShikiko UenoKazutaka OdaNao GundaYumi ShimomuraYuka NishimuraAyami YamaguchiAkari KuwanoYuki ItoYusuke BabaAina NishigakiNatsumi MichiwakiShota UchinoKayo KurogiYawara KawanoMasao MatsuokaHideyuki SaitoYutaka OkunoHirofumi JonoMDPI AGarticlemultiple myelomabortezomibdiarrheaserum concentrationdiscontinuationNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5674, p 5674 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	multiple myeloma bortezomib diarrhea serum concentration discontinuation Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	multiple myeloma bortezomib diarrhea serum concentration discontinuation Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Yuki Fujimoto Shikiko Ueno Kazutaka Oda Nao Gunda Yumi Shimomura Yuka Nishimura Ayami Yamaguchi Akari Kuwano Yuki Ito Yusuke Baba Aina Nishigaki Natsumi Michiwaki Shota Uchino Kayo Kurogi Yawara Kawano Masao Matsuoka Hideyuki Saito Yutaka Okuno Hirofumi Jono Relationship between Serum Bortezomib Concentration and Emergence of Diarrhea in Patients with Multiple Myeloma and/or AL Amyloidosis
description	(1) Background: multiple myeloma patients have benefited from bortezomib therapy, though it has often been discontinued owing to diarrhea. The objective of this study was to verify serum bortezomib concentration in the emergence of diarrhea. (2) Methods: this prospective, observational case-control, and monocentric study was performed with an approval by the Ethics Committee of Kumamoto University Hospital in 2015 (No. 1121) from February 2015 to April 2017. (3) Results: twenty-four patients with bortezomib therapy were recruited; eight patients (33.3%) developed diarrhea at day 3 as median. Median measured trough bortezomib concentration at 24 h after first or second dose for patients with or without diarrhea was 0.87 or 0.48 ng/mL, respectively (<i>p =</i> 0.04, Wilcoxon signed rank test). Receiver operation characteristic (ROC) analysis produced the cut-off concentration of 0.857 ng/mL (area under the ROC curve of 0.797, sensitivity of 0.625, specificity of 0.875). The survival curves between patients with and without diarrhea were similar (<i>p =</i> 0.667); those between patients with higher and lower concentration than median value (0.61 ng/mL) were also similar (<i>p =</i> 0.940). (4) Conclusions: this study indicated the possible involvement of serum bortezomib concentration in the emergence of diarrhea in bortezomib therapy in patients with multiple myeloma.
format	article
author	Yuki Fujimoto Shikiko Ueno Kazutaka Oda Nao Gunda Yumi Shimomura Yuka Nishimura Ayami Yamaguchi Akari Kuwano Yuki Ito Yusuke Baba Aina Nishigaki Natsumi Michiwaki Shota Uchino Kayo Kurogi Yawara Kawano Masao Matsuoka Hideyuki Saito Yutaka Okuno Hirofumi Jono
author_facet	Yuki Fujimoto Shikiko Ueno Kazutaka Oda Nao Gunda Yumi Shimomura Yuka Nishimura Ayami Yamaguchi Akari Kuwano Yuki Ito Yusuke Baba Aina Nishigaki Natsumi Michiwaki Shota Uchino Kayo Kurogi Yawara Kawano Masao Matsuoka Hideyuki Saito Yutaka Okuno Hirofumi Jono
author_sort	Yuki Fujimoto
title	Relationship between Serum Bortezomib Concentration and Emergence of Diarrhea in Patients with Multiple Myeloma and/or AL Amyloidosis
title_short	Relationship between Serum Bortezomib Concentration and Emergence of Diarrhea in Patients with Multiple Myeloma and/or AL Amyloidosis
title_full	Relationship between Serum Bortezomib Concentration and Emergence of Diarrhea in Patients with Multiple Myeloma and/or AL Amyloidosis
title_fullStr	Relationship between Serum Bortezomib Concentration and Emergence of Diarrhea in Patients with Multiple Myeloma and/or AL Amyloidosis
title_full_unstemmed	Relationship between Serum Bortezomib Concentration and Emergence of Diarrhea in Patients with Multiple Myeloma and/or AL Amyloidosis
title_sort	relationship between serum bortezomib concentration and emergence of diarrhea in patients with multiple myeloma and/or al amyloidosis
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/e6d83d1c31f744fe8db46174da7bb086
work_keys_str_mv	AT yukifujimoto relationshipbetweenserumbortezomibconcentrationandemergenceofdiarrheainpatientswithmultiplemyelomaandoralamyloidosis AT shikikoueno relationshipbetweenserumbortezomibconcentrationandemergenceofdiarrheainpatientswithmultiplemyelomaandoralamyloidosis AT kazutakaoda relationshipbetweenserumbortezomibconcentrationandemergenceofdiarrheainpatientswithmultiplemyelomaandoralamyloidosis AT naogunda relationshipbetweenserumbortezomibconcentrationandemergenceofdiarrheainpatientswithmultiplemyelomaandoralamyloidosis AT yumishimomura relationshipbetweenserumbortezomibconcentrationandemergenceofdiarrheainpatientswithmultiplemyelomaandoralamyloidosis AT yukanishimura relationshipbetweenserumbortezomibconcentrationandemergenceofdiarrheainpatientswithmultiplemyelomaandoralamyloidosis AT ayamiyamaguchi relationshipbetweenserumbortezomibconcentrationandemergenceofdiarrheainpatientswithmultiplemyelomaandoralamyloidosis AT akarikuwano relationshipbetweenserumbortezomibconcentrationandemergenceofdiarrheainpatientswithmultiplemyelomaandoralamyloidosis AT yukiito relationshipbetweenserumbortezomibconcentrationandemergenceofdiarrheainpatientswithmultiplemyelomaandoralamyloidosis AT yusukebaba relationshipbetweenserumbortezomibconcentrationandemergenceofdiarrheainpatientswithmultiplemyelomaandoralamyloidosis AT ainanishigaki relationshipbetweenserumbortezomibconcentrationandemergenceofdiarrheainpatientswithmultiplemyelomaandoralamyloidosis AT natsumimichiwaki relationshipbetweenserumbortezomibconcentrationandemergenceofdiarrheainpatientswithmultiplemyelomaandoralamyloidosis AT shotauchino relationshipbetweenserumbortezomibconcentrationandemergenceofdiarrheainpatientswithmultiplemyelomaandoralamyloidosis AT kayokurogi relationshipbetweenserumbortezomibconcentrationandemergenceofdiarrheainpatientswithmultiplemyelomaandoralamyloidosis AT yawarakawano relationshipbetweenserumbortezomibconcentrationandemergenceofdiarrheainpatientswithmultiplemyelomaandoralamyloidosis AT masaomatsuoka relationshipbetweenserumbortezomibconcentrationandemergenceofdiarrheainpatientswithmultiplemyelomaandoralamyloidosis AT hideyukisaito relationshipbetweenserumbortezomibconcentrationandemergenceofdiarrheainpatientswithmultiplemyelomaandoralamyloidosis AT yutakaokuno relationshipbetweenserumbortezomibconcentrationandemergenceofdiarrheainpatientswithmultiplemyelomaandoralamyloidosis AT hirofumijono relationshipbetweenserumbortezomibconcentrationandemergenceofdiarrheainpatientswithmultiplemyelomaandoralamyloidosis
_version_	1718412810544742400

Relationship between Serum Bortezomib Concentration and Emergence of Diarrhea in Patients with Multiple Myeloma and/or AL Amyloidosis

Ejemplares similares